Search for "viaskin"

Dave Bloom - 2018/12/21 0

The company believes the additional information needed to support this filing is available without further clinical studies.

News Wire ~ 3rd Party Press Release - 2018/10/23 0

"This submission represents a significant step forward for those families living with peanut allergy."

News Wire ~ 3rd Party Press Release - 2018/09/12 0

Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.

Dave Bloom - 2017/11/20 0

The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.

Dave Bloom - 2017/10/24 0

The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.

Dave Bloom - 2017/03/07 0

Pediatric patients responded with a favorable safety profile and no serious adverse effects.

Dave Bloom - 2016/10/25 0

The study was designed to assess the long-term efficacy and safety of the treatment in subjects that had graduated from their earlier VIPES trial.

Dave Bloom - 2016/03/07 5

We are cautiously optimistic that a safe, effective, easy to administer treatment for food allergy may be on the horizon.

Dave Bloom - 2015/06/30 0

The board overseeing the Phase I study of the milk allergy therapy found no safety concerns.

Dave Bloom - 2022/12/26 0

The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.

viaskin - search results